Oncology

News
Augtyro

FDA widens label for BMS’ cancer drug Augtyro

Bristol-Myers Squibb has claimed FDA approval for a new, tumour-agnostic indication for Augtyro, the cancer drug it acquired as part of its $4.1 billion takeover of Turning Point Therapeuti

Oncology
ASCO24

Four takeaways from ASCO24

Last weekend, I travelled to Chicago for the annual conference of the American Society of Clinical Oncologists— the annual event where major breakthroughs in cancer care are announced.

Oncology
diversity in clinical trials

Building resilience in cancer trials

Clinical trials are a cornerstone of oncology research, vital for turning scientific breakthroughs into effective cancer treatments.

R&D
Dr Suzanne Trudel at ASCO 2024

ASCO 2024 - Suzanne Trudel

Sometimes getting a new drug to market is a relatively straight line, but sometimes it’s a winding road.